Sponsors (2)
The bill aims to improve targeted infectious, allergic, and immunologic research and clarify leadership by splitting NIAID into specialized institutes, but does so at the cost of short-term transition costs, potential coordination slowdowns, and a risk of politicized leadership selection.
Researchers and public-health systems will get three specialized institutes focused on infectious, allergic, and immunologic diseases, improving targeted research and outbreak response capabilities.
Federal employees and research programs will have presidentially appointed institute directors with fixed 5-year terms, creating clearer leadership accountability for each disease area.
State governments and health systems will face clearer statutory authorities and program jurisdiction after a statutory reorganization, reducing legal ambiguity over which institute oversees specific programs.
Scientists, research programs, and taxpayers may face short-term administrative disruption and transition costs that divert funding away from active research.
Patients with chronic conditions and health systems may experience slower decision-making and reduced coordination across related research areas during the transition to three separate institutes.
Scientists and patients risk politicization of research priorities because institute directors are presidentially appointed, which could influence hiring, funding, and research agendas.
Based on analysis of 2 sections of legislative text.
Splits the National Institute of Allergy and Infectious Diseases into three institutes (allergic, infectious, immunologic) and establishes new leadership appointment rules and statutory reassignments.
Creates three separate Institutes out of the current National Institute of Allergy and Infectious Diseases (NIAID): one for allergic diseases, one for infectious diseases, and one for immunologic diseases. It rewrites statutory references so programs and authorities move to the appropriate new institutes, ends the single NIAID Director position on enactment, and establishes presidential appointment terms for the three new Directors. Requires an orderly transition of authorities and transfers existing statutory provisions into new statutory locations; it does not itself change funding levels but alters institutional structure and leadership appointment rules.
Introduced February 20, 2025 by Rand Paul · Last progress February 20, 2025